On Friday, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) opened lower -3.87% from the last session, before settling in for the closing price of $8.52. Price fluctuations for CRVS have ranged from $1.30 to $10.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -65.36% at the time writing. With a float of $49.95 million, this company’s outstanding shares have now reached $64.26 million.
Let’s look at the performance matrix of the company that is accounted for 28 employees. In terms of profitability, gross margin is 70.73%, operating margin of -10200.81%, and the pretax margin is -23102.85%.
Corvus Pharmaceuticals Inc (CRVS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Corvus Pharmaceuticals Inc is 22.27%, while institutional ownership is 28.57%. The most recent insider transaction that took place on May 06 ’24, was worth 34,624. In this transaction an insider of this company bought 20,000 shares at a rate of $1.73, taking the stock ownership to the 153,773 shares. Before that another transaction happened on May 06 ’24, when Company’s President and CEO bought 577,634 for $1.73, making the entire transaction worth $1,000,000. This insider now owns 577,634 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.14 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.13) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -65.36% per share during the next fiscal year.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
Check out the current performance indicators for Corvus Pharmaceuticals Inc (CRVS). In the past quarter, the stock posted a quick ratio of 0.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) saw its 5-day average volume 1.22 million, a positive change from its year-to-date volume of 0.37 million. As of the previous 9 days, the stock’s Stochastic %D was 31.42%. Additionally, its Average True Range was 0.78.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 78.06%, which indicates a significant increase from 18.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.74% in the past 14 days, which was lower than the 84.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.83, while its 200-day Moving Average is $3.44. Nevertheless, the first resistance level for the watch stands at $8.54 in the near term. At $8.89, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.27. If the price goes on to break the first support level at $7.81, it is likely to go to the next support level at $7.43. Assuming the price breaks the second support level, the third support level stands at $7.08.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Key Stats
There are currently 64,257K shares outstanding in the company with a market cap of 505.89 million. Presently, the company’s annual sales total 0 K according to its annual income of -27,030 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -4,260 K.
